T1	Participants 157 192	advanced colorectal cancer patients
T2	Participants 615 694	advanced colorectal cancer (ACC) patients treated in the phase III CAIRO2 study
T3	Participants 718 780	Seven hundred and fifty five previously untreated ACC patients
T4	Participants 1116 1153	Seven hundred and thirty two patients
